These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8305838)

  • 21. CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis.
    Eymael J; Sharma S; Loeven MA; Wetzels JF; Mooren F; Florquin S; Deegens JK; Willemsen BK; Sharma V; van Kuppevelt TH; Bakker MA; Ostendorf T; Moeller MJ; Dijkman HB; Smeets B; van der Vlag J
    Kidney Int; 2018 Mar; 93(3):626-642. PubMed ID: 29276101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathy.
    Morita M; Mii A; Shimizu A; Yasuda F; Shoji J; Masuda Y; Ohashi R; Nagahama K; Kaneko T; Tsuruoka S
    PLoS One; 2015; 10(4):e0116700. PubMed ID: 25875837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [THE CHARACTERISTICS OF CYTOKINE STATUS UNDER DIFFERENT CLINICAL VARIANTS OF GLOMERULONEPHRITIS].
    Karzakova LM; Avtonomova OI; Stepanova IM; Komeliagina NA; Kudriashov SI
    Klin Lab Diagn; 2015 Jun; 60(6):33-6. PubMed ID: 26466449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy.
    Schulze M; Donadio JV; Pruchno CJ; Baker PJ; Johnson RJ; Stahl RA; Watkins S; Martin DC; Wurzner R; Gotze O
    Kidney Int; 1991 Sep; 40(3):533-8. PubMed ID: 1787650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical analysis of molecular events in tubulo-interstitial fibrosis in a mouse model of diffuse mesangial sclerosis (ICGN strain).
    Mizuno S; Mizuno-Horikawa Y; Kurosawa T
    J Vet Med Sci; 2001 Mar; 63(3):299-307. PubMed ID: 11307931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Focal segmental glomerular sclerosis: the cellular lesion.
    Schwartz MM; Lewis EJ
    Kidney Int; 1985 Dec; 28(6):968-74. PubMed ID: 4087702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depletion of clusterin in renal diseases causing nephrotic syndrome.
    Ghiggeri GM; Bruschi M; Candiano G; Rastaldi MP; Scolari F; Passerini P; Musante L; Pertica N; Caridi G; Ferrario F; Perfumo F; Ponticelli C
    Kidney Int; 2002 Dec; 62(6):2184-94. PubMed ID: 12427144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Membrane attack complex deposition in experimental glomerular injury.
    Perkinson DT; Baker PJ; Couser WG; Johnson RJ; Adler S
    Am J Pathol; 1985 Jul; 120(1):121-8. PubMed ID: 3160245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloperoxidase-antineutrophil cytoplasmic antibody causes different renal diseases by immune-complex formation and pauci-immune mechanism: A case report.
    Manabe S; Hatano M; Nakano M; Fujii T; Nitta K; Nagata M
    Pathol Int; 2017 Aug; 67(8):419-424. PubMed ID: 28580649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical pathology of the glomerulus--from phenomenon to entity. Focal sclerosis].
    Waldherr R; Derks H
    Verh Dtsch Ges Pathol; 1989; 73():71-82. PubMed ID: 2482637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating antibodies to α-enolase and phospholipase A
    Kimura Y; Miura N; Debiec H; Morita H; Yamada H; Banno S; Ronco P; Imai H
    Clin Exp Nephrol; 2017 Feb; 21(1):117-126. PubMed ID: 26830547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo.
    Shankland SJ; Floege J; Thomas SE; Nangaku M; Hugo C; Pippin J; Henne K; Hockenberry DM; Johnson RJ; Couser WG
    Kidney Int; 1997 Aug; 52(2):404-13. PubMed ID: 9263996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of immune-deposit formation and the mediation of immune renal injury.
    Nangaku M; Couser WG
    Clin Exp Nephrol; 2005 Sep; 9(3):183-91. PubMed ID: 16189625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
    Guerry MJ; Vanhille P; Ronco P; Debiec H
    Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
    [No Abstract]   [Full Text] [Related]  

  • 36. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats.
    Floege J; Eng E; Young BA; Alpers CE; Barrett TB; Bowen-Pope DF; Johnson RJ
    J Clin Invest; 1993 Dec; 92(6):2952-62. PubMed ID: 7902849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.
    Yang Y; Gubler MC; Beaufils H
    Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent insights into the pathogenesis of nephrotic syndrome.
    Certikova-Chabova V; Tesar V
    Minerva Med; 2013 Jun; 104(3):333-47. PubMed ID: 23748287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of calcium-independent phospholipase A2 in complement-mediated glomerular epithelial cell injury.
    Cohen D; Papillon J; Aoudjit L; Li H; Cybulsky AV; Takano T
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F469-79. PubMed ID: 18171998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of platelets in progressive glomerular diseases.
    Zoja C; Remuzzi G
    Pediatr Nephrol; 1995 Aug; 9(4):495-502. PubMed ID: 7577419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.